Aligos Therapeutics, Inc. (ALGS)

Market Cap	33.03M -44.4%
Revenue (ttm)	31.52M +893.0%
Net Income	-75.96M
EPS	-7.31
Shares Out	6.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,466
Open	5.40
Previous Close	5.23
Day's Range	5.19 - 5.41
52-Week Range	3.98 - 13.69
Beta	2.36
Analysts	Strong Buy
Price Target	52.38 (+890.17%)
Est. Earnings	Nov 5, 2026

About ALGS

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protea...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 82
• Stock Exchange: Nasdaq
• Ticker Symbol: ALGS
• Website: https://www.aligos.com

Financial Performance

In 2025, Aligos Therapeutics's revenue was $2.19 million, a decrease of -44.59% compared to the previous year's $3.95 million. Losses were -$24.19 million, -81.56% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for ALGS stock is "Strong Buy." The 12-month stock price target is $52.38, which is an increase of 890.17% from the latest price.

Price Target

$52.38

(890.17% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error